Treatment of non-infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ-cyclodextrin nanoparticle eye drops.
Treatment of non-infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ-cyclodextrin nanoparticle eye drops.
复制标题
1.5%地塞米松γ-环糊精纳米颗粒滴眼液治疗非感染性眼科炎症性疾病
DOI：
10.1111/aos.14119
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Tanito M
中科院分区：
文献类型：
--
作者：
Imamachi K;Stefánsson E;Ohira A;Tanito M
在停用1.5%地塞米松-环糊精纳米颗粒滴眼液后8周，在右眼中未观察到黄斑水肿（E），而在左眼中观察到黄斑水肿复发（F）。gl使用1.5% DexNP滴眼液治疗前后巩膜炎和Vogt-Koyanagi-Harada病相关的视乳头炎之前尚未报道。在Vogt-Koyanagi-Harada病的情况下（病例4），治疗开始后脉络膜厚度降低，表明脉络膜病变也可以是1.5% DexNP滴眼液的治疗靶点。[摘自文章] Acta Ophthalmologica（1755375 X）的版权是Wiley-Blackwell的财产，未经版权保持器的明确书面许可，不得将其内容复制或通过电子邮件发送到多个网站或发布到列表服务器。但是，用户可以打印，下载或电子邮件的文章供个人使用。这篇摘要可以删节。不保证副本的准确性。用户应参考原始出版版本的材料的完整摘要。版权适用于所有摘要。
At 8 weeks after the discontinuation of 1.5% dexamethasone-cyclodextrin nanoparticle eye drops, no macular oedema is observed in right eye (E) while the recurrence of macular oedema is observed in left eye (F). gl Use of 1.5% DexNP eye drops for the treatment of anterior and posterior scleritis and Vogt-Koyanagi-Harada disease-related papillitis has not been previously reported. In case of Vogt-Koyanagi-Harada disease (Case 4), choroidal thickness decreased after the start of treatment, suggests that choroidal lesion also can be a treatment target of 1.5% DexNP eye drops.[Extracted from the article]Copyright of Acta Ophthalmologica (1755375X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.